Fuda Cancer Hospital
Pancreatic cancer treatment cost in China typically includes diagnostics like gastroscopy, which ranges from $100 to $600, and major procedures like Whipple surgery costing $28,500 to $62,500. Total expenses depend on the clinical stage, surgical approach, and hospital tier. Patients can save approximately 50-85% compared to the US. Top treatment centers are located in Guangzhou, Beijing, and Shanghai.
Typical Pancreatic Cancer Treatment Costs in China
Bookimed Expert Insight: Late-stage patients seeking alternatives to traditional chemotherapy find high value in Chinese specialized centers. Fuda Cancer Hospital in Guangzhou is a world-renowned facility specializing in minimally invasive therapies. Dr. Niu Lizhi at Fuda has performed nearly 500 NanoKnife procedures for complex cases. This JCI-accredited hospital offers advanced options like cryosurgery and vascular interventional therapy for patients from over 100 countries.
| China | Turkey | Austria | |
| Whipple surgery | from $28,500 | from $16,200 | from $45,000 |
| Tomotherapy | from $17,500 | from $12,000 | from $30,000 |
| Proton-beam therapy | from $36,500 | from $70,000 | from $80,000 |
| Pancreatic cancer surgery | from $25,000 | from $9,000 | from $40,000 |
| NanoKnife | from $22,500 | from $9,500 | from $25,000 |
Chief physician and professor. Grade 1 Expert at the Cancer Center, West China Hospital, Sichuan University (ranked No. 2 in China). Completed a postdoctoral fellowship in interventional radiology at the Chinese PLA General Hospital. Leads multidisciplinary team (MDT) care for complex tumors. Expert in minimally invasive interventional oncology for liver, lung, and pancreatic cancers.
Accreditations: Council Member, WATA. Member of CACA and CMDA committees on intervention, ablation, radioactive seeds, and pain. In 2023, inaugural director member, Palliative Care Committee, Sichuan MDA. Editorial board member of the Chinese Journal of Interventional Imaging and Therapy. Editorial board member of the Chinese Journal of Pain Medicine.
Leads 2 provincial S&T projects and 2 NSFC projects. Has 40+ papers, with 30+ as first or corresponding author. Highest impact factor: 10.73. Hepatocellular carcinoma (HCC) cohort: TACE + lenvatinib vs TACE + sorafenib. OS 18.97 vs 10.77 months. PFS 10.6 vs 5.4 months. ORR 66.8% vs 33.3%.
Professor Luo Xiaoping is a nationally recognized interventional radiologist and a leading authority in Western China. He began pioneering vascular interventions in the early 1990s. He helped found the Interventional Group at the Second Affiliated Hospital of Chongqing Medical University.
He has completed over 100,000 interventional procedures, including about 4,000 complex cases. His key skills include TACE for hepatocellular carcinoma, Budd–Chiari interventions, TIPS, and single-stage bilateral stenting for hilar biliary obstruction, with success rates near 100%. He has been a master’s supervisor since 2007. He has trained many physicians, guided complex cases at more than 40 major hospitals across Western China, and helped build interventional programs. He has published 32 papers as first or corresponding author (22 CSCD core, 4 Chinese core, 6 CSCD extended).
Dr. He Weibing is a pioneer of argon-helium cryoablation in China with more than 20 years of frontline practice. He was a founding member of Fuda Cancer Hospital (Guangzhou). He co-founded its Minimally Invasive Tumor Treatment Center and served as Executive Deputy Director. He also helped found the Ablation Group of the China Anti-Cancer Association. He has been the primary operator in more than 10,000 procedures.
He specializes in tumor cryoablation and is proficient in 125I seed brachytherapy, with a focus on liver and lung cancers. He proposed ten argon-helium techniques. Key co-authored data include: lung cryotherapy n=508; NSCLC n=120 (CR 25.5%, PR 41.8%, 6/12/24-month survival 64%/55%/36%); pancreatic cancer n=38 (median survival 12 months). He served on editorial boards in 2008 and 2010. He has been a national trainer for Varian and Boston Scientific since 2001.
Professor Xiao Yueyong is Chief Physician in the Department of Radiological Diagnosis at the Chinese PLA General Hospital. He is a leading expert in minimally invasive interventional oncology. He serves as the inaugural President of WATA (2025–). He is President of the International (2020–) and Asian (2012–) Societies of Cryotherapy. He is also Deputy Head of the NHC Expert Group on tumour ablation regulations (2009–).
He has performed over 100,000 CT/MRI‑guided minimally invasive procedures. His work covers chemical ablation, RFA, MWA, cryoablation, and NanoKnife (IRE). He introduced and advanced NanoKnife ablation in China. He led the first national standards for tumour cryoablation and NanoKnife.
Honors include the National Special Contribution Award (Lifetime Honorary). He received First Prize from the Chinese Medicine Education Association (2021). He received two Second Prizes for Military Medical Achievements (2016, 2018) and two Second Prizes from the China Anti‑Cancer Association (2019, 2022). He was named Asian Ablation Master. His research record includes 13 Chinese patents. He is the principal investigator for four NSFC projects and one MOST subject. He has published over 200 papers, with over 110 as first or corresponding author and over 40 in SCI journals. He has led over 10 ablation guidelines or consensus statements.
Advanced treatments in China include minimally invasive ablation, robotic surgery, and precision radiotherapy for late-stage cases. JCI-accredited facilities offer NanoKnife irreversible electroporation and cryosurgery to treat inoperable tumors. These centers combine Western medical technology with integrated therapies to improve patient outcomes and quality of life.
Bookimed Expert Insight: China has emerged as a global leader in non-thermal ablation, particularly for tumors near critical structures. While many Western centers reserve NanoKnife for clinical trials, Chinese specialists like Dr. Niu Lizhi have performed over 500 such procedures. This high volume often leads to refined protocols for treating patients aged 4 to 94 years.
Patient Consensus: Patients value how Chinese specialists attempt to save organs rather than immediately recommending full removals. They often note that high-tech equipment helps clarify diagnoses that were previously uncertain in their home countries.
Post-operative recovery in China follows Enhanced Recovery After Surgery (ERAS) and Multidisciplinary Team (MDT) protocols. International patients typically remain hospitalized for 10 to 14 days. Care integrates modern surgical monitoring with traditional Chinese medicine to accelerate physical rehabilitation and manage common side effects like nausea.
Bookimed Expert Insight: While Chinese oncology centers like Fuda Cancer Hospital hold JCI accreditation, recovery experiences differ for international visitors. High-volume specialists like Dr. Niu Lizhi have performed over 10,000 cryosurgeries. This expertise often leads to organ-sparing outcomes. However, patients should budget for VIP room upgrades. These private suites ensure a quieter environment for recovery than standard shared wards.
Patient Consensus: Patients note that using traditional herbal soups and acupuncture helps reduce post-surgical nausea. Many recommend hiring a private nurse or using translation apps to bridge language gaps with hospital staff.
Chinese pancreatic surgeons at major oncology centers are highly experienced and often hold international recognition. Leading specialists manage extreme case volumes. Some elite surgeons have performed over 10,000 procedures. Many work in JCI-accredited facilities. They frequently pioneer advanced techniques for complex, late-stage cases.
Bookimed Expert Insight: High-volume centers in China offer a distinct advantage for complex resections. Specialized surgeons often perform hundreds of pancreatic procedures annually. For example, Dr. Niu Lizhi has completed over 500 NanoKnife operations. This repeated exposure to rare scenarios typically ensures higher precision and better outcomes.
Patient Consensus: Patients note that top Chinese clinics prioritize organ preservation over radical removal. They appreciate the detailed diagnostic explanations and high-tech equipment available at specialized oncology hospitals.
Typical hospital stays for pancreatic cancer surgery in China range from 13 to 20 days. Specialized recovery protocols at top centers can reduce this to 10 days for uncomplicated cases. Patients must remain nearby for 1 to 2 weeks post-discharge to manage potential surgical complications.
Bookimed Expert Insight: While major centers report stays of 20 days, specialized oncology hospitals like Fuda Cancer Hospital focus on minimally invasive cryosurgery and NanoKnife. These advanced techniques, performed by surgeons like Dr. Niu Lizhi, often allow for faster mobility compared to traditional open Whipple procedures.
Patient Consensus: Patients note that while inpatient stays in China are often shorter than in Western countries, complications like bile leaks are possible. They emphasize staying in a nearby hotel for at least 3 weeks to handle follow-up bloodwork and wound care before flying home.
Chinese oncology centers minimize barriers through dedicated international departments and multidisciplinary teams. Facilities like Fuda Cancer Hospital hold JCI accreditation. They employ bilingual coordinators to manage medical inquiries and on-site interpretation. Specialized wings provide medical records in English to simplify follow-up care for overseas patients.
Bookimed Expert Insight: High-volume centers like Fuda Cancer Hospital, which has treated over 30,000 patients from 100 countries, create institutional memory for specific cultural needs. For example, Professor Niu Lizhi has performed over 10,000 cryosurgeries on a diverse global population. This massive volume means staff are naturally accustomed to navigating varied international expectations without needing formal scripts.
Patient Consensus: Patients note that high-tech equipment is world-class, but they often recommend joining local WeChat groups for real-time advice. Many suggest that while doctors are skilled, having a private translator helps ensure no details are lost during complex post-op discussions.
Patients undergoing pancreatic surgery in China generally require an S1 or S2 medical visa. Standard tourist visas are restricted to minor services. An official invitation from a Tier-3 hospital is mandatory. Applicants must also provide financial proof covering 120% of estimated costs.
Bookimed Expert Insight: While many hospitals require immediate out-of-pocket payments, choosing JCI-accredited centers like Fuda Cancer Hospital simplifies the transition for international patients. Their experience with over 30,000 global patients means they are better equipped to handle the specific documentation needed for S-type visas. Additionally, packages like CyberKnife at Jinshazhou Hospital often include clinic transfers. This is a vital detail because local transport in cities like Guangzhou rarely assists patients with limited mobility after major abdominal surgery.
Patient Consensus: Patients note it is essential to set up Alipay or WeChat Pay before arrival as hospitals are nearly cashless. Most emphasize that traveling with a family member is necessary for help with pain management and discharge logistics.
Leading cities for comprehensive pancreatic cancer care include Guangzhou, Heidelberg, and Tel Aviv. These hubs feature Joint Commission International (JCI) accredited facilities with high surgical volumes. They offer advanced interventions like NanoKnife, CyberKnife M6, and cryosurgery. Specialized departments ensure multidisciplinary coordination for international patients.
Bookimed Expert Insight: Guangzhou stands out for treating late-stage pancreatic cancer using minimally invasive cryosurgery. Professor Niu Lizhi at Fuda Cancer Hospital has performed nearly 10,000 cryosurgeries. This high volume is rare globally. While many centers focus on traditional surgery, these Chinese facilities prioritize organ-saving techniques. Some packages for CyberKnife M6 in Guangzhou cost around $7,900 for the procedure.
Patient Consensus: Patients note China's high-tech equipment often provides diagnostic clarity when other countries fail. They emphasize having a local translator to navigate complex hospital systems and digital payment requirements.